Ritonavir

Drugs of the Future

Volumn 21, Issue 7, 1996, Pages 700-705

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR;

ANTIVIRAL ACTIVITY; BIOAVAILABILITY; DRUG METABOLISM; DRUG RESISTANCE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; SHORT SURVEY; VIRUS INFECTION;

EID: 0029761245     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.07.366079     Document Type: Short Survey

References (26)

1. Kempf, D.J., Norbeck, D.W., Sham, H.L. et al. (Abbott Labs.). Retroviral protease inhibiting cpds. EP 674513, WO 9414436.
2. Al-Razzak, L., Marsh, K.C., Manning, L.P., Kaul, D. (Abbott Labs.). Pharmaceutical compsns. containing HIV protease inhibitors. US 5484801, WO 9520384.
3. Flentge, C., Kempf, D., Marsh, K. et al. Symmetry-based inhibitors of HIV protease with high oral bioavailability. 207th ACS Natl Meet (March 13-17, San Diego) 1994, Abst MEDI 35.
4. Mealy, N., Castañer, J. Indinavir sulfate. Drugs Fut 1996, 21(6): 600-9.
5. Kempt, D., Markowitz, M., Marsh, K. et al. Pharmacokinetic and in vitro selection studies with ABT-538, a potent inhibitor of HIV protease with high oral bioavailability. 34th Intersci Conf Antimicrob Agents Chemother (Oct 4-7, Orlando) 1994, Abst A/4.
6. Kempf, D.J., Marsh, K.C., Denissen, J.F. et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995, 92: 2484-8.
7. Hsu, A., Granneman, R., Rynkiewicz, K., Valdes, J., Mayer, K., Leonard, J. Kinetics of ABT-538, a protease inhibitor, in humans after single oral rising doses. Pharm Res 1994, 11(10, Suppl.): Abst PPDM 8272.
8. Hsu, A., Granneman, R., Witt, G., Locke, C., Erdman, K., Smith, J., Valdes, J., Leonard, J. Pharmacokinetics of ritonavir after Q12H dosing in HIV-positive patients. 5th Eur Conf Clin Aspects Treat HIV Infect (Sept 26-29, Copenhagen) 1995, Abst 566.
9. Cato, A., Hsu, A., Granneman, R., Leonard, J., Carlson, G., Carothers, L., Cao, G.-L. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and fluconazole. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst 133.
10. Cato, A., Hsu, A., Granneman, R., Leonard, J., Carlson, G., Carothers, L., Locke, C. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and zidovudine. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst 134.
11. Cato, A., Qian, J., Carothers, L., Carlson, G., Locke, C., Hsu, A., Granneman, R., Leonard, J. Evaluation of the pharmacokinetic interaction between ritonavir and didanosine. Clin Pharmacol Ther 1996, 59(2): Abst PI-59.
12. Kumar, G.N., Rodrigues, A.D., Buko, A.M., Denissen, J.F. Cytochrome P450-mediated human liver microsomal metabolism of the HIV-1 protease inhibitor ABT-538. 4th Int ISSX Meet (Aug 27-31, Seattle) 1995, Abst 86.
13. Danner, S.A., Cooper, D.A., Gudiol, F., Gonzales, J., Tor, J., Rubio, R., Valdes, J., Leonard, J.M. Safety, pharmacokinetics and virological/immunological efficacy of ABT-538, a HIV-protease inhibitor. A randomised, placebo-controlled phase I/II study. AIDS 1994, 8(Suppl. 4): Abst 11.2.
14. Markowitz, M., Saag, M., Powderly, W.G. et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New Engl J Med 1995, 333: 1534-9.
15. Danner, S.A., Carr, A., Leonard, J.M. et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. New Engl J Med 1995, 333: 1528-33.
16. Markowitz, M., Jalil, L., Hurley, A., Farthing, C., Cao, Y., Saag, M., Powderly, W., Valdes, J., Leonard, J. Evaluation of the antiviral activity of orally administered ABT-538, an inhibitor of HIV-1 protease. 2nd Natl Conf Hum Retroviruses Relat Infect (Jan 29-Feb 2, Washington DC) 1995, Abst 185.
17. Kelleher, A.D., Carr, A., Zaunders, J., Cooper, D.A. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173: 321-9.
18. Korneyeva, M., Boucher, C., Niu, P., Schipper, P., Lyons, N., Kempf, D.J., Leonard, J., Norbeck, D.W., Molla, A. Phenotypic and genotypic evolution of HIV-1 in AIDS patients undergoing therapy with the protease inhibitor ABT-538. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst I175.
19. Kempf, D.J., Flentge, C., Marsh, K.C. et al. Symmetry-based inhibitors of HIV protease: Oral bioavailability and resistance emergence. J Cell Biochem Suppl 1994, 18(Part D): Abst S 038.
20. Markowitz, M., Mo, H., Kempf, D., Norbeck, D., Ho, D.D. Selection and analysis of HIV-1 variants with reduced susceptibility to an inhibitor of HIV-1 protease. J Cell Biochem Suppl 1994, 18(Part B): Abst J 521.
21. Mo, H., Markowitz, M., Ho, D.D. Patterns of specific mutations in HIV-1 protease that confer resistance to a panel of protease inhibitors. 2nd Natl Conf Hum Retroviruses Relat Infect (Jan 29-Feb 2, Washington DC) 1995, Abst 188.
22. Markowitz, M., Mo, H., Kempf, D.J., Norbeck, D.W., Bhat, T.N., Erickson, J.W., Ho, D.D. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995, 69: 701-6.
23. Gao, Q., Stewart, K., Park, C., Dave, A., Kempf, D.J., Leonard, J., Norbeck, D.W., Molla, A. Specific mutations in HIV-1 protease that confer diminished susceptibility to ABT-538. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst I282.
24. FDA approves second protease inhibitor to treat HIV. Food and Drug Administration Press Release 1996, March 1.
25. Second protease inhibitor approved for HIV therapy. Amer J Health-Syst Pharm 1996, 53: 832.
26. New product intros. Drug News Perspect 1996, 9: 164.